Posted by Michael Wonder on 28 May 2025
Fresenius Kabi to announce the commercial launch of Otulfi, an approved ustekinumab biosimilar in Canada
27 May 2025 - Fresenius Kabi's ustekinumab biosimilar Otulfi is now commercially available for both subcutaneous and intravenous formulations.
Fresenius Kabi Canada announces that its ustekinumab biosimilar, developed by Formycon AG, is now commercially available in Canada.
